Related Experiment Video
Updated: Jun 23, 2026

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
Targeting THOC2-Mediated mRNA Export Induces PARP Inhibitor Vulnerability in DNA Repair-Competent Hepatocellular
Xinli Li1, Songpeng Yang1, Mengxin Zhang1
1State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Beijing 102206, China.
Abstract:
Hepatocellular carcinoma (HCC) remains a lethal malignancy with limited therapeutic options. While Poly (ADP-ribose) polymerase inhibitors (PARPi) exploit synthetic lethality in tumors with DNA repair defects, their clinical utility in HCC is hindered by the low prevalence of canonical repair gene mutations and the enhancing DNA repair capacity. Through proteomic analysis of two independent cohorts (n=260), we identified the THO complex component THOC2 as a master regulator of DNA damage response (DDR) via mRNA nuclear export control. Clinically, THOC2 overexpression predicted poor survival (HR=2.68-6.84, P<0.001) and correlated with enhanced DDR gene expression. Mechanistically, THOC2 chaperones mRNA nuclear export of DDR effectors (MDC1, PRKDC, MSH6) and proliferation drivers (TOP2A), thereby establishing a dual pro-repair/pro-growth program. Targeting this vulnerability, THOC2 knockdown induced synthetic lethality with PARPi, reducing Olaparib IC50 by up to 61% and suppressing tumor growth by 76% (P<0.001). Our study illuminates mRNA transport as a druggable DDR modulator and establishes THOC2 as both a prognostic biomarker and a therapeutic target to overcome PARPi resistance in HCC. This work pioneers a strategy to expand synthetic lethality beyond genetic defects by targeting post-transcriptional regulation.
Insights
THOC2 regulates DNA damage response (DDR) by controlling mRNA export. Targeting THOC2 with Poly (ADP-ribose) polymerase inhibitors (PARPi) shows promise for treating hepatocellular carcinoma (HCC) by inducing synthetic lethality.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Hepatocellular carcinoma (HCC) presents limited therapeutic options due to low mutation rates in DNA repair genes.
- Poly (ADP-ribose) polymerase inhibitors (PARPi) are effective in tumors with DNA repair defects, but their utility in HCC is restricted.
- Enhanced DNA repair capacity in HCC limits the efficacy of conventional treatments.
Purpose of the Study:
- To identify novel regulators of DNA damage response (DDR) in hepatocellular carcinoma (HCC).
- To investigate the role of THO complex component 2 (THOC2) in DDR and its potential as a therapeutic target.
- To explore strategies for overcoming PARPi resistance in HCC.
Main Methods:
- Proteomic analysis of two independent HCC cohorts (n=260).
- Investigated THOC2's role in mRNA nuclear export of DDR and proliferation-related genes.
- Assessed the synergistic effect of THOC2 knockdown and PARPi (Olaparib) on HCC cell lines and tumor growth.
Main Results:
- THOC2 was identified as a master regulator of DDR through mRNA nuclear export control.
- THOC2 overexpression correlated with poor HCC patient survival and increased DDR gene expression.
- THOC2 knockdown induced synthetic lethality with PARPi, significantly reducing Olaparib efficacy and suppressing tumor growth.
Conclusions:
- THOC2 is a prognostic biomarker and therapeutic target for hepatocellular carcinoma (HCC).
- Targeting mRNA transport offers a novel strategy to modulate DDR and overcome PARPi resistance.
- This study expands the concept of synthetic lethality beyond genetic defects to include post-transcriptional regulation in cancer therapy.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Abnormal Proliferation
